| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Cost-effectiveness perspectives in coronary heart disease
|
Goldman, Lee
|
|
1990
|
119 |
3P2 |
p. 733-740
8 p.
|
artikel
|
| 2 |
Costs and benefits of risk factor reduction for coronary heart disease: Insights from screening and treatment of serum cholesterol
|
Stason, William B.
|
|
1990
|
119 |
3P2 |
p. 718-724
7 p.
|
artikel
|
| 3 |
Introduction
|
Mancia, Giuseppe
|
|
1990
|
119 |
3P2 |
p. 711-
1 p.
|
artikel
|
| 4 |
Measuring costs and financial benefits in randomized controlled trials
|
Bulpitt, Christopher J.
|
|
1990
|
119 |
3P2 |
p. 766-771
6 p.
|
artikel
|
| 5 |
Medical management and managing medical care: The dilemma of evaluating new technology
|
Bloom, Bernard S.
|
|
1990
|
119 |
3P2 |
p. 754-761
8 p.
|
artikel
|
| 6 |
Outcome assessment in cardiovascular cost-benefit studies
|
O'Brien, Bernard
|
|
1990
|
119 |
3P2 |
p. 740-748
9 p.
|
artikel
|
| 7 |
Overview: Economic evaluation and coronary heart disease
|
Mancia, Giuseppe
|
|
1990
|
119 |
3P2 |
p. 775-776
2 p.
|
artikel
|
| 8 |
Regulatory demands for cost-benefit studies
|
Louis, William J.
|
|
1990
|
119 |
3P2 |
p. 771-775
5 p.
|
artikel
|
| 9 |
Stratifying the patient at risk from coronary disease: New insights from the framingham heart study
|
Levy, Daniel
|
|
1990
|
119 |
3P2 |
p. 712-717
6 p.
|
artikel
|
| 10 |
The cost-benefit approach to pricing new medicines: Doxazosin versus β-blocker treatment in Sweden
|
Lindgren, Björn
|
|
1990
|
119 |
3P2 |
p. 748-753
6 p.
|
artikel
|
| 11 |
The design of future cost-benefit studies
|
Maynard, Alan
|
|
1990
|
119 |
3P2 |
p. 761-765
5 p.
|
artikel
|
| 12 |
The economics of hypertension and stroke
|
Smith, George Teeling
|
|
1990
|
119 |
3P2 |
p. 725-728
4 p.
|
artikel
|
| 13 |
Treating hypertension and cardiovascular risk: Are there trade-offs?
|
Grimm Jr, Richard H.
|
|
1990
|
119 |
3P2 |
p. 729-732
4 p.
|
artikel
|
Tijdschrift beschrijving